Evidence map›Paper›PMID 36176406›Full record

ArticleFrontiers in oncology2022

Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report.

Yu Zhang, Hao Zhang, Hanqing Wang, Jingtong Zeng, Bo Zhang, Ning Zhou, Lingling Zu, Zuoqing Song, Changli Wang, Song Xu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. [Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 
Skipping Mutation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yu ZhangDepartment of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Hao ZhangDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Hanqing WangDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Jingtong ZengDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Bo ZhangDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Ning ZhouDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Lingling ZuDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Zuoqing SongDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Changli WangDepartment of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Song XuDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Tianjin Medical University General Hospital · CNTianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Savolitinib is a tyrosine kinase inhibitor being developed for the treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) factor exon 14 skipping alterations. However, the role of savolitinib in neoadjuvant therapy for lung cancer remains unclear. Here, we present a case of a 65-year-old woman diagnosed with stage IIIA (cT2bN2M0, eighth TNM stage) upper right lung adenocarcinoma harboring MET exon 14 skipping alterations. After 4 weeks of therapy, a partial response was achieved with neoadjuvant savolitinib, and significant shrinkage in tumor and lymph nodes was observed. We also measured the immune microenvironment of the primary tumor pre- and posttreatment with savolitinib.

Indexed as

MET exon 14 skippingneoadjuvantNSCLCsavolitinibtargeted therapy

Identifiers

PMID36176406
PMCPMC9514319
OpenAlexW4297252864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.